GuidonACBurtonLBChwaliszBK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer2021; 9: e002890.
2.
KumarNAbboudH.Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler2019; 25(8): 1079–1085.
3.
WillisMRobertsonNP.Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf2014; 13(8): 1115–1124.
4.
StorkLBrückWvon GottbergP, et al. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. Mult Scler2019; 25(12): 1618–1632.
5.
KimTBrinkerACorteauD, et al. Immune-mediated colitis associated with ocrelizumab: A new safety risk. Mult Scler2023.
6.
MallepallyNAbu-SbeihHAhmedO, et al. Clinical features of rituximab-associated gastrointestinal toxicities. Am J Clin Oncol2019; 42(6): 539–545.
7.
KristjánssonVBLundSHGröndalG, et al. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scand J Gastroenterol2021; 56(1): 46–52.
8.
KosmidouMKatsanosAHKatsanosKH, et al. Multiple sclerosis and inflammatory bowel diseases: A systematic review and meta-analysis. J Neurol2017; 264(2): 254–259.
9.
PerumalJSKisterIHowardJ, et al. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm2015; 2(1): e61.
10.
KellyHJohnsonJJakubeczC, et al. Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic. J Neuroimmunol2022; 370: 577928.
11.
BrummerTRuckTMeuthSG, et al. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord2021; 14: 17562864211035542.
